Scinai shares surge 13.37% premarket as investors anticipate AGM vote on CEO compensation.

Scinai Immunotherapeutics (NASDAQ:SCNI) surged 13.37% in premarket trading following news that it will hold its Annual General Meeting on December 22nd and disclosed CEO Amir Reichman’s compensation details. The announcement highlighted that Reichman’s total pay of $659,000, including a $338,000 salary, is 47% below the industry average for similarly sized biotech firms. This below-median compensation, combined with the upcoming shareholder vote on executive pay, may have signaled cost discipline and alignment with shareholder interests, potentially boosting investor confidence. While the company reported a 97% shareholder loss over three years, the disclosed EPS growth of 85% and the focus on cost control likely contributed to the premarket rally. The AGM provides shareholders an opportunity to influence management, which could be perceived as a positive governance development.